The following type of technologies are available for licensing:
- A monoclonal antibody specific for a novel marker of angiogensis (patent pending). Balza et al. (2009) “A novel fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B.” Int J Cancer 125:751-758. Ventura et al. (2010) “Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8″. PLoS ONE 5(2):e9145.
- A novel procedure for the generation of stable and soluble polyvalent-polyspecific recombinant proteins (patent pending). Ventura et al. (2009) “Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.” J Biol Chem 284:26646-26654.
